- In 2026, Hong Kong-listed companies have shifted from aggressive expansion to prioritizing cash flow, dividends, and survival resilience amid a changing capital market.
- Mature enterprises like Haidilao, Shui On Land, and China Resources Gas are emphasizing stable profits and generous dividends, while firms like Leapmotor and Cloud Village are seeking strategic alliances and commercialization.
- Meanwhile, biotech companies such as Conal, Akeso-like entities, and others are navigating rigorous clinical and commercialization milestones to prove their fundamental business value.